Production (Stage)
SpringWorks Therapeutics, Inc.
SWTX
$46.68
$0.220.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -253.93M | -258.13M | -275.16M | -301.06M | -339.07M |
| Total Depreciation and Amortization | 3.84M | 3.47M | 2.99M | 2.61M | 2.14M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 122.11M | 116.93M | 116.18M | 112.29M | 108.15M |
| Change in Net Operating Assets | -37.44M | -37.86M | -52.82M | -47.72M | -11.13M |
| Cash from Operations | -165.43M | -175.60M | -208.80M | -233.89M | -239.91M |
| Capital Expenditure | -3.90M | -4.45M | -1.10M | -2.87M | -4.99M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.38M | 69.00M | -107.71M | -99.98M | -37.40M |
| Cash from Investing | 116.48M | 64.55M | -108.81M | -102.85M | -42.39M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.52M | 13.20M | 311.35M | 309.58M | 305.30M |
| Repurchase of Common Stock | -14.81M | -8.44M | -8.17M | -7.93M | -7.37M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -5.29M | 4.76M | 303.18M | 301.65M | 297.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -54.25M | -106.29M | -14.43M | -35.09M | 15.64M |